お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
949660

コンパニオン診断の世界市場:2020~2026年

Global Companion Diagnostics Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.27円
コンパニオン診断の世界市場:2020~2026年
出版日: 2020年06月27日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のコンパニオン診断の市場は予測期間中に大幅な成長を示すと予測されています。標的治療および精密医療への認知度の高まり、次世代シーケンシング技術への注力の拡大、コンパニオン診断の用途の拡大などの要因が同市場の成長を推進しています。地域別では、北米地域が大きなシェアを占める見通しです。高度に成熟し、技術的に進歩した医療インフラを備えた米国は、コンパニオン診断市場に大きく貢献しています。また、アジア太平洋地域は予測期間中に大幅な成長を示すと予測されています。プロテオミクスおよびゲノミクス研究の拡大、特にインド、中国、韓国、日本における個別化医療の開発の活発化などの要因が同地域の成長を推進しています。

当レポートでは、世界のコンパニオン診断の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、関連法規制、市場規模の推移・予測、バスタイプ・電池タイプ・エンドユーザーなど各種区分別の内訳、競合環境、企業シェア、主要企業のプロファイルなどをまとめています。

第1章 レポート概要

第2章 市場概要・考察

  • 調査範囲
  • アナリストの見解・現在の市場動向
  • 法規制

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略の分析
  • 主要企業の分析

第4章 市場影響因子

  • 成長推進因子
  • 成長抑制因子
  • 市場機会

第5章 市場分析・予測:各種区分別

  • 技術別
    • PCR
    • In Situハイブリダイゼーション(ISH)
    • 免疫組織化学(IHC)
    • 次世代シーケンス(NGS)
    • その他(遺伝子配列決定)
  • 適応症別
    • 乳癌
    • 肺癌
    • 黒色腫
    • 神経疾患
    • その他(胃癌)

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他
  • その他の地域

第7章 企業プロファイル

  • Abbott Laboratories
  • Abnova Corp.
  • Agilent Technologies, Inc.
  • Almac Group
  • Amgen Inc.
  • AstraZeneca PLC
  • Biocartis NV
  • bioMerieux SA
  • F. Hoffmann-La Roche Ltd.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Leica Biosystems
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Promega Corp.
  • Protagen AG
  • QIAGEN NV
  • Siemens AG
  • Sysmex Corp.
  • Thermo Fisher Scientific Inc.
図表

LIST OF TABLES

  • 1. GLOBAL COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2019-2026 ($ MILLION)
  • 2. GLOBAL PCR MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL ISH MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL IHC MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL NGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL OTHER TECHNOLOGIES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 8. GLOBAL COMPANION DIAGNOSTICS FOR BREAST CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL COMPANION DIAGNOSTICS FOR LUNG CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL COMPANION DIAGNOSTICS FOR MELANOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL COMPANION DIAGNOSTICS FOR NEUROLOGICAL DISEASES MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 12. GLOBAL OTHER INDICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 13. GLOBAL COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 17. EUROPEAN COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2019-2026 ($ MILLION)
  • 19. EUROPEAN COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 21. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2019-2026 ($ MILLION)
  • 22. ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)
  • 23. REST OF THE WORLD COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2019-2026 ($ MILLION)
  • 24. REST OF THE WORLD COMPANION DIAGNOSTICS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE BY TECHNOLOGY, 2019 VS 2026 (%)
  • 2. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE BY INDICATION, 2019 VS 2026 (%)
  • 3. GLOBAL COMPANION DIAGNOSTICS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD COMPANION DIAGNOSTICS MARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2021979

Global Companion Diagnostics Market Size, Share & Trends Analysis Report by Technology (Polymerase Chain Reaction (PCR), In Situ Hybridization (ISH), Immunohistochemistry (IHC), Next-Generation Sequencing (NGS), and Others) and by Indication (Breast Cancer, Lung Cancer, Melanoma, Neurological Diseases, and Others) and Forecast 2020-2026

The global companion diagnostics market is projected to witness considerable growth during the forecast period. The major factors contributing to the growth of the market include the growing awareness of targeted therapy and precision medicine, increasing focus on next-generation sequencing technologies, and growing application of companion diagnostics. The companion diagnostics market is classified on the basis of technology and indication. Based on technology, the market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), and others. Based on indication, the market is segregated into breast cancer, lung cancer, melanoma, neurological diseases, and others. Among these indications, the companion diagnostics finds a significant application in lung cancer, owing to the presence of some of companion diagnostics tests that are made mandatory for the test of targeted therapies for lung cancer.

Geographically, the global companion diagnostics market is segmented into North America, Europe, Asia-Pacific, and Rest of the World. North America is expected to contribute a significant share in the global market. The US with a highly matured and technologically advanced healthcare infrastructure, contributes considerably in the companion diagnostics market. The presence of huge regulatory bodies such as FDA, further contributes in the increase in the development and test of drugs through such testing tools, which in turn, offers growth to the companion diagnostics market in North America. In addition, Asia-Pacific is expected to project a considerable growth during the forecast period. This growth is backed by the rise in proteomics and genomics research and increasing development of personalized medicine in the region, especially in India, China, South Korea, and Japan.

The global companion diagnostics market is influenced by product development and advancements conducted by the market players. The key players of the companion diagnostics market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., bioMerieux SA, Thermo Fisher Scientific Inc., Promega Corp., QIAGEN NV, Myriad Genetics, Inc., AstraZeneca PLC, and Merck Co. & Inc. These players are playing a significant role in the growth of the companion diagnostics market by providing various products and adopting several strategies such as merger and acquisition, partnerships and collaboration, technological development, and others.

Research Methodology

The market study of the global companion diagnostics market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary sources include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions.

Market Segmentation:

1. Global Companion Diagnostics Market Research and Analysis by Technology

2. Global Companion Diagnostics Market Research and Analysis by Indication

The Report Covers:

  • Comprehensive research methodology of the global companion diagnostics market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global companion diagnostics market.
  • Insights about market determinants which are stimulating the global market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Abbott Laboratories
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. F. Hoffmann-La Roche Ltd.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. bioMerieux SA
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Myriad Genetics, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. QIAGEN NV
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Companion Diagnostics Market by Technology
    • 5.1.1. Polymerase Chain Reaction (PCR)
    • 5.1.2. In Situ Hybridization (ISH)
    • 5.1.3. Immunohistochemistry (IHC)
    • 5.1.4. Next-Generation Sequencing (NGS)
    • 5.1.5. Others (Gene Sequencing)
  • 5.2. Global Companion Diagnostics Market by Indication
    • 5.2.1. Breast Cancer
    • 5.2.2. Lung Cancer
    • 5.2.3. Melanoma
    • 5.2.4. Neurological Diseases
    • 5.2.5. Others (Gastric Cancer)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Abbott Laboratories
  • 7.2. Abnova Corp.
  • 7.3. Agilent Technologies, Inc.
  • 7.4. Almac Group
  • 7.5. Amgen Inc.
  • 7.6. AstraZeneca PLC
  • 7.7. Biocartis NV
  • 7.8. bioMerieux SA
  • 7.9. F. Hoffmann-La Roche Ltd.
  • 7.10. Guardant Health, Inc.
  • 7.11. Illumina, Inc.
  • 7.12. Leica Biosystems
  • 7.13. Merck & Co., Inc.
  • 7.14. Myriad Genetics, Inc.
  • 7.15. Promega Corp.
  • 7.16. Protagen AG
  • 7.17. QIAGEN NV
  • 7.18. Siemens AG
  • 7.19. Sysmex Corp.
  • 7.20. Thermo Fisher Scientific Inc.
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.